American Oncology Network, Inc.
American Oncology Network, Inc. Fundamental Analysis
American Oncology Network, Inc. (AONC) shows weak financial fundamentals with a PE ratio of 655.43, profit margin of 0.03%, and ROE of -2.46%. The company generates $2.1B in annual revenue with strong year-over-year growth of 37.55%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 22.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze AONC's fundamental strength across five key dimensions:
Efficiency Score
WeakAONC struggles to generate sufficient returns from assets.
Valuation Score
WeakAONC trades at a premium to fair value.
Growth Score
ExcellentAONC delivers strong and consistent growth momentum.
Financial Health Score
ModerateAONC shows balanced financial health with some risks.
Profitability Score
WeakAONC struggles to sustain strong margins.
Key Financial Metrics
Is AONC Expensive or Cheap?
P/E Ratio
AONC trades at 655.43 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, AONC's PEG of 17.68 indicates potential overvaluation.
Price to Book
The market values American Oncology Network, Inc. at 8.62 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 18.52 times EBITDA. This signals the market has high growth expectations.
How Well Does AONC Make Money?
Net Profit Margin
For every $100 in sales, American Oncology Network, Inc. keeps $0.03 as profit after all expenses.
Operating Margin
Core operations generate 1.02 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-2.46 in profit for every $100 of shareholder equity.
ROA
American Oncology Network, Inc. generates $0.05 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
American Oncology Network, Inc. generates limited operating cash flow of $-35.02M, signaling weaker underlying cash strength.
Free Cash Flow
American Oncology Network, Inc. generates weak or negative free cash flow of $-62.72M, restricting financial flexibility.
FCF Per Share
Each share generates $-2.14 in free cash annually.
FCF Yield
AONC converts -8.24% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
655.43
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
17.68
vs 25 benchmark
P/B Ratio
Price to book value ratio
8.62
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.37
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
7.85
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.53
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.02
vs 25 benchmark
ROA
Return on assets percentage
0.001
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How AONC Stacks Against Its Sector Peers
| Metric | AONC Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 655.43 | 29.45 | Worse (Expensive) |
| ROE | -2.46% | 779.00% | Weak |
| Net Margin | 0.03% | -24936.00% (disorted) | Weak |
| Debt/Equity | 7.85 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.53 | 4.65 | Neutral |
| ROA | 0.05% | -19344.00% (disorted) | Weak |
AONC outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews American Oncology Network, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
428.50%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-139.40%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-128.89%
Industry Style: Defensive, Growth, Innovation
Declining